Literature DB >> 10893590

Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers.

P Albers1, A Ganz, E Hannig, W D Miersch, S C Müller.   

Abstract

PURPOSE: We evaluated the prognostic criteria for salvage surgery in patients with persistent marker elevation after chemotherapy for metastatic germ cell tumors.
MATERIALS AND METHODS: Of 125 men who underwent post-chemotherapeutic resection of residual tumors 30 had persistent marker elevation at surgery. This group was subdivided into 17 patients with no evidence of disease, 7 dead of disease and 6 others. Outcome analysis was performed in the subgroups with regard to preoperative and postoperative parameters. Mean followup was 120.3 months (range 1 to 228) after surgery.
RESULTS: Of the 30 patients 17 (57%) with persistently elevated tumor markers after chemotherapy were long-term survivors after salvage surgery. Overall persistent viable cancer and teratomatous elements were identified in 64% and 11% of cases, respectively. Significantly more patients died of disease who had a poor prognosis according to International Germ Cell Cancer Collaborative Group guidelines. Embryonal carcinoma was the predominant initial histology in this group and residual disease was more often located at various sites, for example the viscera, with a lower chance of complete surgical resection. Marker status before surgery, and chemotherapeutic pretreatment and postoperative histological findings did not differ significantly in patients with no evidence of disease and those dead of disease.
CONCLUSIONS: Salvage surgery results in long-term success in greater than 50% of patients. Complete resection is the most important single parameter for a favorable outcome. Even patients with visceral metastasis benefit from surgery. Our data do not justify omitting surgery in certain subgroups.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10893590

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  The efficacy of radio-frequency ablation for metastatic lung or liver tumors of male germ cell tumors as an alternative minimally invasive therapy after salvage chemotherapy.

Authors:  Yoshio Naya; Terukazu Nakamura; Masakatsu Oishi; Takashi Ueda; Hiroyuki Nakanishi; Yasuyuki Naitoh; Fumiya Hongo; Kazumi Kamoi; Koji Okihara; Osamu Tanaka; Takuji Yamagami; Kei Yamada; Tsuneharu Miki
Journal:  Int J Clin Oncol       Date:  2015-04-30       Impact factor: 3.402

Review 2.  [Lymphadenectomy for testicular cancer. Diagnostic and prognostic significance as well as therapeutic benefit].

Authors:  S Krege; H Rübben
Journal:  Urologe A       Date:  2005-06       Impact factor: 0.639

Review 3.  Surgical salvage in patients with advanced testicular cancer: indications, risks and outcomes.

Authors:  Ryan W Speir; Clint Cary; Timothy A Masterson
Journal:  Transl Androl Urol       Date:  2020-01

Review 4.  Current Management of Refractory Germ Cell Tumors and Future Directions.

Authors:  J Clayton Allen; Austin Kirschner; Kristen R Scarpato; Alicia K Morgans
Journal:  Curr Oncol Rep       Date:  2017-02       Impact factor: 5.075

5.  [The role of tumour markers in diagnosis and management of testicular germ cell tumours].

Authors:  S Krege; P Albers; A Heidenreich
Journal:  Urologe A       Date:  2011-03       Impact factor: 0.639

6.  Management of poor-prognosis testicular germ cell tumors.

Authors:  Kiranpreet Khurana; Timothy D Gilligan; Andrew J Stephenson
Journal:  Indian J Urol       Date:  2010 Jan-Mar

Review 7.  Platinum-refractory germ cell tumors: an update on current treatment options and developments.

Authors:  Christoph Oing; Winfried H Alsdorf; Gunhild von Amsberg; Karin Oechsle; Carsten Bokemeyer
Journal:  World J Urol       Date:  2016-07-23       Impact factor: 4.226

8.  Successful 2-year-long remission following repeated salvage surgery in a patient with chemotherapy-resistant metastatic nonseminomatous germ cell tumor.

Authors:  Hideki Takeshita; Junji Yonese; Yasuhisa Fujii; Satoru Kawakami; Yoshinobu Komai; Yuhei Ohkubo; Shinya Yamamoto; Yuichi Ishikawa; Yasuyuki Seto; Shigekazu Ohyama; Iwao Fukui
Journal:  Int J Clin Oncol       Date:  2007-12-21       Impact factor: 3.402

Review 9.  [Value of retroperitoneal lymphadenectomy for germ cell cancer].

Authors:  S Krege
Journal:  Urologe A       Date:  2009-01       Impact factor: 0.639

10.  Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice.

Authors:  Axel Heidenreich; David Pfister
Journal:  Ther Adv Urol       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.